Evaluation of the Effect of Telmisartan on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 211
- 试验地点
- 36
- 主要终点
- Change From Baseline in Systolic Blood Pressure (SBP)
研究概览
简要总结
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks. Further on, the study will evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Change From Baseline in Systolic Blood Pressure (SBP)
时间窗: Baseline to 3rd visit (4-10 months)
Change From Baseline in Diastolic Blood Pressure (DBP)
时间窗: Baseline to 3rd visit (4-10 months)
Change From Baseline in SCORE (10 Year Risk for Fatal Cardiovascular Event)
时间窗: Baseline to 3rd visit (4-10 months)
A 10 year risk of fatal cardiovascular disease (CVD) in populations at high risk. Minimum 0 percent risk to Maximum 47 percent risk.
Change From Baseline in Framingham CVD Risk Assessment Score
时间窗: Baseline to 3rd visit (4-10 months)
10-year risk for hard coronary heart disease (CHD) outcomes (Myocardial Infarction and coronary death), according to Framingham Heart Study, measured in percent. Low risk (10 or less CHD risk at 10 years), intermediate risk (10-20), high risk (20 or more).
Change From Baseline in Framingham Stroke Risk Assessment Score
时间窗: Baseline to 3rd visit (4-10 months)
The risk assessment tool using data from the Framingham Heart Study to estimate 10-year risk for stroke, measured in percent. Low risk (10 or less stroke risk at 10 years), intermediate risk (10-20), high risk (20 or more).
Change From Baseline in Risk Assessment According to ESH/ESC Guidelines
时间窗: Baseline to 3rd visit (4-10 months)
ESH is the European society of hypertension, and ESC is the European society of cardiology.
次要结局
- Additional Antihypertensive Treatment Pattern at Visit 3 (End of Study)(3rd visit (4-10 months))
- Change in Heart Rate From Baseline to Study End(Baseline to 3rd visit (4-10 months))
- Number of Patients With Adverse Events (AE)(4-10 months)
- Pecentage of Patients That Achieved Target Blood Pressure (BP) Values According to ESH/ESC(3rd visit (4-10 months))
- Number of Participants Not Completing Study(3rd visit (4-10 months))